What is Boundless Bio?
Boundless Bio is a next-generation precision oncology company focused on interrogating extrachromosomal DNA (ecDNA), a novel area of cancer biology. By targeting ecDNA, the company aims to develop transformative therapies for patients suffering from oncogene-amplified cancers. This innovative approach positions Boundless Bio at the forefront of cancer research, seeking to address a critical unmet need in the oncology landscape. The company's strategy involves leveraging deep scientific understanding to create highly targeted treatments.
How much funding has Boundless Bio raised?
Boundless Bio has raised a total of $251.4M across 3 funding rounds:
Series A
$46.4M
Series B
$105M
Series C
$100M
Series A (2019): $46.4M with participation from GT Healthcare Capital Partners, Boxer Capital, Alexandria Venture Investments, City Hill Ventures, Vertex Ventures, and ARCH Venture Partners
Series B (2021): $105M led by RA Capital Management, Fidelity Management & Research Company, Wellington Management, Surveyor Capital, Logos Capital, PFM Health Sciences, Redmile Group, and Nextech Invest
Series C (2023): $100M supported by Bayer, Sectoral Asset Management, and RA Capital Management
Key Investors in Boundless Bio
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies. They aim to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
Bayer
Bayer is a global enterprise in the life science fields of healthcare and nutrition, with divisions in pharmaceuticals, crop science, animal health, and consumer health. They are headquartered in Leverkusen, Germany.
Sectoral Asset Management
Sectoral Asset Management is an investment advisor specializing in managing equities globally within the healthcare sector, offering a range of public and private equity healthcare strategies, including biotech.
What's next for Boundless Bio?
The substantial enterprise-level financing indicates that Boundless Bio is likely in a scaling phase, poised to advance its pipeline through clinical development and potentially expand its research and development capabilities. The strategic nature of the recent investment suggests a focus on key partnerships or market entry initiatives. Investors such as RA Capital Management, Bayer, and Sectoral Asset Management, with their deep expertise in healthcare and biotechnology, are expected to provide not only capital but also strategic guidance to help Boundless Bio navigate the complex path from discovery to patient impact. This backing is crucial for accelerating the development of their ecDNA-targeting therapies.
See full Boundless Bio company page
